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Abstract: Cisplain, a platinum-containing anticancer drug, has been shown to enhance 
DNA repair and to inhibit cell apoptosis, leading to drug resistance. Thus, the combination 
of anticancer drugs with nutritional factors is a potential strategy for improving the efficacy 
of  cisplatin  chemotherapy.  In  this  study,  we  investigated  the  anti-proliferative  effects  
of  a  combination  of  fucoxanthin,  the  major  non-provitamin  A  carotenoid  found  in  
Undaria  Pinnatifida,  and  cisplatin  in  human  hepatoma  HepG2  cells.  We  found  that 
fucoxanthin  (1–10  μΜ)  pretreatment  for  24  h  followed  by  cisplatin  (10  μΜ)  for  24  h 
significantly  decreased  cell  proliferation,  as  compared  with  cisplatin  treatment  alone. 
Mechanistically, we showed that fucoxanthin attenuated cisplatin-induced NFκB expression 
and enhanced the NFκB-regulated Bax/Bcl-2 mRNA ratio. Cisplatin alone induced mRNA 
expression  of  excision  repair  cross  complementation  1  (ERCC1)  and  thymidine 
phosphorylase  (TP)  through  phosphorylation  of  ERK,  p38  and  PI3K/AKT  pathways. 
However, fucoxanthin pretreatment significantly attenuated cisplatin-induced ERCC1 and 
TP mRNA expression, leading to improvement of chemotherapeutic efficacy of cisplatin. 
The results suggest that a combined treatment with fucoxanthin and cisplatin could lead to a 
potentially important new therapeutic strategy against human hepatoma cells.  
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1. Introduction 
Hepatocellular carcinoma (HCC) is the major cause of cancer death in Taiwan and one of the most 
common cancers in the world, accounting for approximately 6% of all human cancers [1,2]. For most 
patients with unresectable HCC, chemotherapy plays an important role in the treatment of HCC [3]. 
Unfortunately,  chemotherapy  has  limited  effect  on  survival  owing  to  multiple  drug  resistance  
(MDR) [4]. Much evidence indicates that the MDR is involved in drug efflux, DNA repair activity, 
and altered survival and apoptotic signaling pathways [5]. Thus, the new therapeutic strategies for 
malignant HCC using combined therapies or combined agents with distinct molecular mechanisms are 
considered more promising for higher therapy efficacy, resulting in better survival. 
Platinum  antitumor  compounds,  such  as  cisplatin  (cis-diamminedichloroplatinum  (II))  and  its 
analogs, have been used widely as a chemotherapeutic drug for a variety of malignancies including 
hepatocellular carcinoma [6]. Platinum can directly bind to intra- and inter-strand DNA molecules to 
form  predominantly  platinum-DNA  adducts  that  ultimately  interfere  with  DNA  transcription  and 
replication and result in cell death [7–9]. Although cisplatin is extensively used in chemotherapy, its 
effectiveness is limited by acquired or intrinsic resistance [10]. A number of mechanisms of cisplatin 
resistance  in  cancer  cells  has  been  recognized:  (1)  increased  reflux;  (2)  increased  inactivation  by 
sulfhydryl  molecules such as  glutathione;  (3) altered expression of proteins  in  signal  transduction 
pathways that control apoptosis; and (4) increased DNA repair [11]. DNA repair pathways that may 
result in platinum-based chemotherapeutic resistance include mismatch repair (MMR) and nucleotide 
excision repair (NER) [12,13]. Excision repair cross-complementation group 1 (ERCC1) is the initial 
enzyme in the NER pathway of DNA repair, and reports have shown that increased mRNA levels of 
ERCC1  are  associated  with  clinical  resistance  to  platinum-based  chemotherapy  in  human  lung,  
gastric,  ovarian,  cervical,  and  colorectal  carcinomas  and  impact  with  the  survival  rate  of  cancer  
patients  [14–18].  In  addition,  thymidine  phosphorylase  (TP),  a  key  enzyme  in  the  pyrimidine 
nucleoside salvage pathway, is known to catalyze the reversible conversion of thymidine to thymine 
and 2-deoxy-D-ribose-1-phosphate [19]. TP expression in various kinds of tumors is higher than that in 
the  adjacent  non-neoplastic  tissues  [20],  and  TP-overexpressed  cell  lines  are  more  resistant  to  
various apoptosis-inducing stimuli such as cisplatin and microtubule-interfering agents, hypoxia, and  
Fas ligands [21–23]. 
Nuclear  transcription  factor  kappa  B  (NFκB),  a  heterodimeric  protein  composed  of  different 
combinations of members of the Rel family of transcription factors, is inactivated in the cytoplasm by 
IκBs,  a  class  of  inhibitor  proteins.  Phosphorylation  of  IκB  by  upstream  kinases  promotes  its 
ubiquitination-dependent degradation, allowing NFκB to translocate to the nucleus and induce target 
genes, which is associated with cell proliferation [24], angiogenesis [25], metastasis [26], suppression 
of apoptosis [27], promotion of oncogenesis [28], and cancer therapy resistance [24]. NFκB is known 
to inhibit apoptosis through induction of anti-apoptotic proteins or suppression of pro-apoptotic genes, 
and the ratio of pro- and antiapoptotic Bcl-2 family members is critical to determine cell susceptibility Mar. Drugs 2013, 11  52 
 
 
to apoptotic insults [29,30]. Much evidence indicates that several anticancer drugs such as cisplatin, 
docetaxel, gemcitabine induce NFκB nuclear translocation and activation of its target genes, thereby 
potentially leading to chemoresistance [31]. For example, it has been reported that increased resistance 
of human cervical carcinoma cells to cisplatin is partly mediated via enhancement of cisplatin-induced 
NFκB activation [32]. Therefore, agents capable of inhibiting NFκB function might be considered as 
an adjuvant approach in combination with chemotherapeutic agents for a variety of cancers.  
Fucoxanthin  is  one  of  the  most  abundant  carotenoids  and  contributes  more  than  10%  of  the 
estimated total  production of carotenoids in  nature [33]. This  carotenoid  has  been shown to  have 
several biological functions, such as antioxidant activity [34–37], anti-obese effect [38,39], antidiabetic 
activity  [40],  antimutagenicity  [41],  anti-inflammation  [42,43],  and  anticancer  effects  [44,45].  
A  previous  report  revealed  that  inhibition  of  proliferation  of  human  hepatoma  HepG2  cells  by 
fucoxanthin is related to cell cycle arrest by downregulation of cyclin D and induction of GADD45A 
gene expression [45–47]. We recently reported that fucoxanthin exhibits anti-drug resistance potential 
and that the effect is likely associated with attenuated interaction between pregnane X receptor (PXR) 
and coactivator (SRC-1), thereby potentially preventing activation of PXR-mediated CYP3A4 and 
MDR1 expression [48]. As the combination of anticancer drugs with nutritional factors is a potential 
strategy for improving the efficacy of chemotherapy, we herein employed human hepatoma HepG2 
cells to determine whether a combination of fucoxanthin and cisplatin may enhance the inhibition of 
cell proliferation. 
2. Results 
2.1. Fucoxanthin Increases the Sensitivity of Cisplatin in HepG2 Cells 
In HepG2 cells treated with cisplatin (2.5–20 μM) for 24 and 48 h, (Figure 1A), we found that 
cisplatin significantly inhibited the cell viability (13% at 24 h and 39% at 48 h, P < 0.05, respectively, 
at 10 μM cisplatin). In addition, fucoxanthin significantly inhibited the cell proliferation of HepG2 by 
17% and 28% after incubation with 10 μM fucoxanthin for 24 h and 48 h, respectively (Figure S1).  
To  investigate  whether  fucoxanthin  increases  the  sensitivity  of  cisplatin  in  HepG2  cells,  we  
pre-incubated HepG2 cells with fucothanxin (1–10 μM) for 24 h followed by incubation with cisplatin 
(2.5–20  μM) for 24 h. Results  reveal  that the cell viability of HepG2 cells  was  significantly  and  
concentration-dependently inhibited (Figure 1B), with an inhibition of 37% at 10 μM fucoxanthin and 
10  μM  cisplatin,  as  compared  with  cisplatin  treatment  alone.  In  addition,  the  combination  of 
fucoxanthin with cisplatin increased early apoptotic cells (PI negative, Annexin V-FITC positive) and 
late  apoptotic  cells  (PI  positive,  Annexin  V-FITC  positive)  (Figure  1C).  The  results  indicate  that 
fucoxanthin enhances the anti-proliferative effect of cisplatin in human hepatoma HepG2 cells. 
   Mar. Drugs 2013, 11  53 
 
 
Figure  1.  Effects  of  cisplatin  (2.5–20  μM)  alone  or  in  combination  with  fucoxanthin  
(1–10 μM) on cell viability of human hepatoma HepG2 cells. (A) Cell viability of HepG2 
cells incubated with cisplatin for 24 and 48 h. (B) Cell viability of HepG2 cells incubated 
with cisplatin (2.5–10 μM) for 24 h after pretreatment with fucoxanthin (1–10 μM) for  
24 h. (C) Apoptotic cells in HepG2 cells incubated with cisplatin (2.5–10 μM) for 24 h 
after pretreatment with fucoxanthin (1–10 μM) for 24 h. Values are means ±  SD, n = 3; 
means without a common letter differ significantly, P < 0.05. 
 
2.2. Fucoxanthin Attenuates the NFκB Expression Induced by Cisplatin and Restores the 
Phosphorylation of IκB-α Inhibited by Cisplatin 
We also evaluated the effect of fucoxanthin on NFκB expression induced by cisplatin in HepG2 
cells, as determined by the EMSA and NFκB reporter gene assays. As shown as in Figure 2A, cisplatin 
(10 μM) most strongly induced NFκB binding activity at 16 h of incubation (by 77%, as compared 
with untreated cells). However, fucoxanthin concentration-dependently attenuated cisplatin-induced Mar. Drugs 2013, 11  54 
 
 
NFκB binding activity, with a 37% inhibition at 5 μM fucoxanthin (Figure 2B). We also showed that 
fucoxanthin significantly and concentration-dependently attenuated cisplatin-induced NFκB luciferase 
activity in a similar pattern to that of NFκB binding activity (Figure 2C). In addition, fucoxanthin 
significantly  and  concentration-dependently  restored  cisplatin-inhibited  IκB-ʱ-phosphorylation  in 
HepG2 cells at 24 h of incubation, as compared with cisplatin treatment alone (Figure 2D).  
Figure  2.  NFκB  expression  in  HepG2  cells  pretreated  with  fucoxanthin  (0–10  μM) 
followed  by  incubation  with  cisplatin  (10  μM).  (A)  NFκB  expression  in  HepG2  cells 
incubated  with  cisplatin  (10  μM)  for  0–48  h;  (B)  NFκB  expression  in  HepG2  cells 
incubated with cisplatin (10 μM) for 16 h after pretreatment with fucoxanthin (1–10 μM) 
for  24  h;  (C)  NFκB  luciferase  activity  expression  in  HepG2  cells  incubated  with  
cisplatin  (10  μM)  for  16  h  after  pretreatment  with  fucoxanthin  (1–10  μM)  for  24  h;  
(D) Phosphorylation of IκBin HepG2 cells incubated with cisplatin (10 μM) for 16 h after 
pretreatment with fucoxanthin (1–10 μM) for 24 h. Values are means ±  SD, n = 3; means 
without a common letter differ significantly, P < 0.05. 
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2.3. Fucoxanthin Combined with Cisplatin Increases the Ratio of Bax/Bcl-2 mRNA Expression in 
HepG2 Cells 
Treatment  of  HepG2  cells  with  cisplatin  (10  μM)  for  24  h  significantly  increased  the  ratio  of 
Bax/Bcl-2 mRNA expression (by 1.8-fold, P < 0.001, as compared with untreated cells). However, 
pretreatment of HepG2 cells with fucoxanthin for 24 h followed by incubation with cisplatin for 24 h 
significantly  and  concentration-dependently  increased  the  ratio  of  Bax/Bcl-2  mRNA  expression  
(by 4.3 fold, P < 0.001, as compared with cisplatin treatment alone) (Figure 3A). To further determine 
whether fucoxanthin in combination with cisplatin enhances the ratio of Bax/Bcl-2 mRNA primarily 
through NFκB-regulated pathways, we pretreated HepG2 cells with fucoxanthin for 24 h followed by 
incubation with an NFκB activation inhibitor (NAI) (10 and 20 μM) for 2 h and then by incubation 
with cisplatin (10 μM) for 24 h. We found that the combination of fucoxanthin, NAI and cisplatin 
synergistically or additively increased the ratio of Bax/Bcl-2 mRNA expression, as compared with the 
NFκB activation inhibitor alone (Figure 3B). Thus, the data indicate that fucoxanthin increases the 
ratio of Bax/Bcl-2 mRNA expression and that this effect is likely associated with inhibition of the 
NFκB pathway. 
Figure 3. (A) The ratio of Bax/Bcl-2 mRNA in HepG2 cells pretreated with fucoxanthin  
(1–10 μM) for 24 h followed by incubation with cisplatin (10 μM) for 24 h. (B) The ratio 
of Bax/Bcl-2 mRNA in HepG2 cells pretreated with fucoxanthin (5 μM) for 24 h followed 
by  incubation  with  NFκB  activation  inhibitor  (NAI,  20  μΜ)  for  2  h  and  then  treated 
cisplatin (10 μM) for 24 h. Values are means ±  SD, n = 3; means without a common letter 
differ significantly, P < 0.05. 
A  B 
   
2.4. Fucoxanthin Attenuates mRNA Expression of ERCC1 and TP Induced by Cisplatin  
Real-time PCR was  performed to  evaluate the  mRNA levels  of ERCC1 and  TP. As shown in  
Figure 4, cisplatin (10 μM) treatment alone significantly increased the mRNA expression of ERCC1 
and TP in HepG2 cells. However, the induced mRNA expression of ERCC1 and TP in HepG2 cells  
by cisplatin (10 μM) was attenuated by pretreatment with fucoxanthin (1–10 μM) for 24 h, with a  
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1.5-fold and a 1.2-fold inhibition, respectively, at 10 μM fucoxanthin, as  compared with cisplatin 
treatment alone.  
Figure 4. The level of ERCC1 and TP mRNA in HepG2 cells pretreated with fucoxanthin 
(1–10 μM) for 24 h followed by incubation with cisplatin (10 μM) for 24 h. Values are 
means ±  SD, n = 3; means without a common letter differ significantly, P < 0.05. 
 
2.5. Fucoxanthin Attenuates the Phosphorylation of ERK1/2, p38, AKT and PI3K in HepG2 Cells 
The time effect of cisplatin on protein expression of the mitogen-activated protein kinase (MAPK) 
family (p38, ERK, and JNK) and  phosphatidylinositol 3-kinase (PI3K)/AKT in HepG2 cells were 
determined  by  Western  blotting.  Results  reveal  that  cisplatin  (10  μM)  markedly  increased  the 
phosphorylation  of  ERK,  p38  and  PI3K/AKT  at  6  h  of  incubation,  but  it  did  not  affect  the 
phosphorylation  of  JNK  or  the  protein  expression  of  ERK,  p38  and  JNK  (Figure  5A).  We  then 
determined whether pretreatment of HepG2 cells with fucoxanthin (1–10 μM) for 24 h attenuates the 
induction of MAPK family and PI3K/AKT protein expression by cisplatin (10 μM). We found that 
fucoxanthin concentration-dependently attenuated cisplatin-induced phosphorylation of ERK, p38 and 
PI3K/AKT (Figure 5B).  
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Figure  5.  The  protein  expression  of  MAPK  family  and  PI3K/AKT  in  HepG2  cells 
pretreated with fucoxanthin (0–10 μM) followed by incubation with cisplatin (10 μM).  
(A) The protein expression of MAPK family and PI3K/AKT in HepG2 cells incubated 
with  cisplatin  (10  μM)  for  0–24  h.  (B)  The  protein  expression  of  MAPK  family  and 
PI3K/AKT in HepG2 cells incubated with cisplatin (10 μM) for 6 h after pretreatment with 
fucoxanthin (1–10 μM) for 24 h.  
 
2.6. Effect of Fucoxanthin in Combination with ERK, p38 and PI3K Inhibitor on ERCC1 and  
TP mRNA Expression in HepG2 Cells 
We then determined whether the attenuation of fucoxanthin on ERCC1 and TP mRNA expression 
induced by cisplatin occur primarily through the inhibition of ERK, p38 and PI3K/AKT pathway. 
HepG2 cells were pre-incubated with fucoxanthin (5 μM) for 24 h followed by incubation with ERK 
inhibitor (PD98059; 20 μM), p38 inhibitor (SB203580; 20 μM) or PI3K inhibitor (LY294002; 20 μM) 
for 1 h and then with cisplatin (10 μM) for 24 h. The concentration of 5 μM fucoxanthin was chosen 
because it only produced a slight inhibition of mRNA expression for ERCC1 and TP (see Figure 4). 
We found that the combination of fucoxanthin, cisplatin and the ERK inhibitor or PI3K inhibitor 
synergistically inhibited ERCC1 mRNA expression but not TP mRNA expression (Figure 6A,B). In 
contrast,  the  combination  of  fucoxanthin  with  p38  inhibitor  enhanced  the  inhibition  of  mRNA 
expression of TP but not ERCC1 (Figure 6C). Thus, the results reveal that fucoxanthin may inhibit 
ERCC1  mRNA  expression  through  ERK  and  PI3K/AKT  pathway  but  may  inhibit  TP  mRNA 
expression through p38 pathway.  
   Mar. Drugs 2013, 11  58 
 
 
Figure 6. The level of ERCC1 and TP mRNA in HepG2 cells pretreated with fucoxanthin 
(5 μM) for 24 h followed by incubation with a specific inhibitor (20 μM) for 1 h and then 
treated  cisplatin  (10  μM)  for  24  h.  (A)  ERK  inhibitor  (PD98059);  (B)  PI3K  inhibitor 
(LY294002); (C) p38 inhibitor (SB203580). Values are means ±  SD, n = 3; means without 
a common letter differ significantly, P < 0.05. 
 
3. Discussion 
The main question addressed by this study was whether a combination of fucoxanthin and cisplatin 
improves the efficacy of chemotherapy and enhances the inhibition of cell proliferation. Our data 
demonstrate  for  the  first  time  that  fucoxanthin  in  combination  with  cisplatin  inhibits  the  cell 
proliferation  of  human  hepatoma  HepG2  cells  and  that  this  combined  effect  involves  NFκB  
mediated-pathways and attenuation of the DNA repair gene expression induced by cisplatin.  
A  probable  mechanism  by  which  fucoxanthin  improves  the  efficacy  of  cisplatin  chemotherapy  
is  through  the  inhibition  of  NFκB  expression  and  the  increase  in  NFκB-regulated  Bax/Bcl-2  
mRNA expression. NFκB is known to suppress apoptosis through the loss of pro-apoptotic factors  
(e.g., functional p53 or Bax) or the activation of anti-apoptotic factors such as Bcl-2, Bcl-XL or IAPs 
(Inhibitors of Apoptosis Proteins) to block caspase-8 activation [24]. Moreover, NFκB binding sites Mar. Drugs 2013, 11  59 
 
 
were found in the promoter of Bcl-2, Bcl-xL, and survivin [49], suggesting that these apoptotic factors 
may be regulated by NFκB. Overexpression of the antiapoptotic molecules Bcl-2 or Bcl-xL can cause 
resistance  to  anticancer  drugs  [50].  We  found  that  fucoxanthin  pretreatment  attenuated  
cisplatin-induced DNA-binding activity of NFκB, restored cisplatin-inhibited IκB-ʱ-phosphorylation, 
and increased the ratio of Bax/Bcl-2 mRNA expression, rendering cancer cells sensitive to apoptosis 
induced  by  cisplatin.  Many  NFκB  inhibitors  have  been  identified  in  vitro  such  as  proteasome  
inhibitors, genistein, parthenolide, flavopiridol and gliotoxin, enhance the cytotoxic effect of anticancer  
agents  [29].  In  the  present  study,  we  found  that  fucoxanthin  strongly  attenuated  cisplatin-induced 
NFκB activation, suggesting that fucoxanthin may be an NFκB inhibitor.  
Another  probable  mechanism  by  which  fucoxanthin  improves  the  efficacy  of  cisplatin 
chemotherapy is through the inhibition of mRNA expression of DNA repair genes ERCC1 and TP. 
Tumor DNA repair capacity is frequently increased as an inherent cellular mechanism for evading cell 
death  as  a result of administration of chemotherapeutic drugs.  Increased expression of ERCC1 in 
several cancers has been associated with more efficient removal of DNA adducts induced by platinum, 
leading to clinical resistance to cisplatin-based chemotherapy [51]. Depletion of endogenous ERCC1 
expression by si-ERCC1 RNA transfection was shown to significantly enhance the cytotoxicity of 
cisplatin [52]. In the present study, we found that fucoxanthin pretreatment significantly attenuated 
cisplatin-induced  ERCC1  and  TP  mRNA  expression.  Recently,  Tsai  et  al.  [53]  have  shown  that 
curcumin downregulates the expression levels of TP and ERCC1, which helps  overcome platinum 
resistance in cancer cells.  
MAPK family and PI3K/AKT pathways play important roles in the regulation of cell proliferation, 
differentiation,  apoptosis  and  DNA  repair  pathways  [54].  Protein  kinase  C  and  Ras  have  been 
suggested to be involved in the activation of ERK1/2 by cisplatin [55]. AKT may promote cell survival 
by phosphorylating and inactivating the pro-apoptotic proteins BAD (Bcl-2-associated death protein) 
and  caspase-9  [56].  It  has  been  reported  that  the  inactivation  of  NFκB-binding  activity  sensitizes 
human ovarian cancer cells to cisplatin in vitro [57] and that the combined therapy of cisplatin with a 
PI3K inhibitor enhances the apoptotic effect of cisplatin in vivo [58]. In this study, we found that 
cisplatin activated the phosphorylation of ERK1/2, p38, AKT and PI3K in human hepatoma HepG2 
cells  and  that  fucoxanthin  pretreatment  attenuated  cisplatin-induced  phosphorylation  of  all  these 
signaling molecules to sensitize cancer cells to apoptosis induced by cisplatin. With regard to the DNA 
repair  system,  it  has  been  shown  that  specific  MERK/ERK  and  PI3K  inhibitors  prevent  ERCC1 
induction,  whereas  JNK  and  p38  inhibitors  are  without  effects  in  human  hepatoma  cells  [59]. 
Interestingly, curcumin and emodin, which are natural anthraquinone derivatives found in the roots and 
rhizomes of numerous plants, were found to enhance cisplatin-induced cytotoxicity via downregulation 
of ERCC1 and inactivation of ERK1/2 in non-small cell lung cancer [52]. The inhibition of the PI3K 
pathway on ERCC1 basal expression has been confirmed by using shRNA against FRAP/mTOR, a 
key kinase involved in nucleotide excision repair pathway [60]. TP, a key enzyme in the pyrimidine 
nucleoside salvage pathway, was  also  found to be  regulated by  NFκB- and p38 MAPK-mediated 
signaling  in  patients  with  nasopharyngeal  carcinoma  [61].  In  the  present  study,  we  found  that 
fucoxanthin inhibited ERCC1 mRNA expression through the ERK and PI3K/AKT pathways, whereas 
this  carotenoid  inhibited  TP  expression  through  the  p38  pathway,  as  evidenced  by  using  specific 
inhibitors. The results indicate that the improved chemotherapeutic efficacy of cisplatin by fucoxanthin Mar. Drugs 2013, 11  60 
 
 
may also involve inhibition of mRNA expression of some DNA repair genes through downregulation 
of ERK, p38, and PI3K/AKT pathways.  
4. Experimental Section  
4.1. Materials 
Dulbecco’s modified eagle medium (DMEM), fetal bovine serum (FBS), trypsin, penicillin, sodium 
pyruvate,  and  non-essential  amino  acids  (NEAA)  were  purchased  from  GIBCO/BRL  (Maryland,  
MD,  USA).  MAPK/extracellular  signal-regulated  kinase  (ERK)  1/2,  c-Jun  NH2-terminal  kinase 
(JNK)/stress-activated  protein  kinase  and  p38  MAPK  proteins  and  phosphorylated  proteins, 
phosphatidylinositol 3-kinase (PI3K)/AKT, ERK inhibitor (PD98059), p38 inhibitor (SB203580) and 
PI3K inhibitor (LY294002) were purchased from Cell Signaling Technology (Beverly, MA). NFκB 
activation  inhibitor was  purchased  from  Merck Millipore (Billerica, MA, USA). Fucoxanthin was 
extracted  from  Undaria  pinnatifida  and  purified,  as  we  reported  previously  [62].  The  purified 
fucoxanthin was dissolved in ethanol to a final concentration of 10 mM as the stock solution. Before 
the experiment, fucoxanthin solutions were prepared freshly in a mixture of ethanol and FBS (1:9), as 
adopted from the preparation of lycopene solution [63].  
4.2. Cell Cultures 
The  human  hepatoblastoma  HepG2  cell  line  was  obtained  from  Food  Industry  Research  and 
Development Institute (FIRDI, Hsinchu, Taiwan) and maintained in DMEM supplemented with 10% 
fetal bovine serum without antibiotics under 5% CO2 at 37 ° C. 
4.3. Assessment of Cell Viability 
Cell viability was evaluated using the modified acid-phosphatase (ACP) assay, with p-nitrophenyl 
phosphate (PNPP) disodium salt as a substrate. The cell culture media were aspirated, and the cells 
were washed with phosphate-buffered saline (PBS). Following the wash, 100 μL of the ACP reagent 
(0.1 M sodium acetate (pH 5.5), 0.1% Triton X-100, and 10 mM PNPP) was added. After 1 h of 
incubation at 37 ° C, the enzyme activity was stopped by adding 10 μL of 1 N NaOH, and the enzyme 
activity was determined photometrically at a wavelength of 405 nm [64]. 
4.4. Real-Time Polymerase Chain Reaction 
Total  RNA  in  cell  cultures  was  extracted  with  REzol  reagent  (PROtech  Technologies,  Inc., 
Placentia, CA, USA), and 1 μg of total RNA was reverse-transcribed by using oligo-dT as a primer in 
20 μL reverse-transcription solutions containing 1 μL reverse transcriptase (Promega, Sunnyvale, CA, 
USA). Real-time PCR performed with a Corbett instrument (Applied Biosystems, Carlsbad, CA, USA) 
using  SYBR  Green  Master  Mix  (ProTech,  Placentia,  CA,  USA)  according  to  the  manufacturer’s 
instructions.  In all real-time PCR experiments, both a non-template control (NTC) and a standard 
curve were amplified, as well. The RNA abundance was normalized to β-actin RNA in each sample. 
The primers used in this study were as follows: ERCC1 forward 5′-CCCTGGGAATTTGGCGAC Mar. Drugs 2013, 11  61 
 
 
GTAA-3′,  reverse  5′-CTCCAGGTACCGCCCAGCTTCC-3′;  TP  forward  5′-AGCTGGAGTCTATT 
CCTGGATT-3′, reverse 5′-GGCTGCATATAGGATTCCGTC-3′; β-actin forward 5′-GTGGGGCGC 
CCCAGGCACCA-3′, reverse 3′-CACCCCGCGGGGTCCGTGGT-5′. 
4.5. Western Blotting 
Protein expression of MAPK family (ERK, p38, JNK, p-JNK, p-ERK and p-p38) and PI3K/AKT 
(PI3K, AKT and p-AKT) was measured by Western blotting. In cell culture experiments, the medium 
was removed and cells were rinsed with PBS twice. After the addition of 0.5 mL of cold RIPA buffer 
and protease inhibitors, cells were scraped and followed by a mild vortexing at 0 ° C for 20 min. The 
cell lysates were then subjected to a centrifugation of 10,000 rpm for 30 min at 4 ° C. Total protein  
(50 μg) from the supernatant was resolved on SDS-PAGE and transferred onto a PVDF membrane. 
After blocking with TBS buffer (20 mmol/L Tris-HCl, 150 mmol/L NaCl, pH 7.4) containing 5% 
nonfat milk, the membrane was incubated with monoclonal antibody followed by incubation with 
horseradish peroxidase-conjugated anti-goat IgG, and then visualized using an ECL chemiluminescent 
detection kit (Amersham, Sweden). The relative density of the immunoreactive bands was quantitated 
by densitometry (Gel Pro Analyzer TM, version 3.0, Media Cybernetics, Rockville, MD, USA). 
4.6. Preparation of Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)  
Nuclear protein extracts (5 μg) were prepared according to the modified method of a previous  
study  [65].  Binding  activities  of  transcription  factors  including  NFκB  were  analyzed  by  EMSA. 
Electrophoretic mobility shift assay (EMSA) was performed with LightShift Chemiluminescent EMSA 
Kit (Pierce Biotechnology, Rockford, IL, Country), as described previously [66]. The NFκB consensus 
oligonucleotide  probe  (5′-AGTTGAGGGGACTTTCCCAGGC-3′)  was  end-labeled  with  biotin 
(Sangon, Shanghai, China). Briefly, nuclear extract (5 μg) was incubated with 10 ng NFκB (p65) 
probe. For the cold probe assay, 40 ng of unlabeled (cold) NFκB probe was mixed with sample 5 min 
before  adding  10  ng  biotin-labeled  NFκB  probe.  Protein-DNA  complexes  were  then  resolved  by  
non-denaturing polyacrylamide gel electrophoresis (PAGE). After blocking, avidin-HRP was applied 
and  detected  by  enhanced  chemiluminescence  (ECL,  Amersham).  The  relative  NFκB  levels  were 
quantitated by Matrox Inspector 2.1 software. 
4.7. Transfection and Luciferase Reporter Gene Assays 
HepG2  cells  (1.8  ×   10
4  cells/well)  were  plated  in  96-microwell-white-plates  (Nalge  Nunc, 
Rochester, New York, NY, USA) before transfection. The NFκB plasmid vector (pGL4.32 (luc2P/ 
NF-κB-RE/Hygro)) contains five copies of an NFκB response element was purchased from Promega 
(Sunnyvale,  CA,  USA).  Transfection  of  NFκB  plasmid  vector  (0.15  μg)  into  HepG2  cells  was 
performed  using  TransIL-LT1  Transfection  Reagent  (Mirus,  Madison,  WI,  USA),  and  in  all 
experiments, the pRL-TK Renilla reporter vector (0.02 μg) (Promega, Sunnyvale, CA, USA) was used 
as an internal control. The cells were then incubated with cisplatin (10 μM) for 16 h after pretreatment 
with fucoxanthin (1–10 μM) for 24 h. Renilla and firefly luciferase activities were measured using the 
Dual-Luciferase Reporter Assay System (Promega, Sunnyvale, CA, USA). Mar. Drugs 2013, 11  62 
 
 
4.8. Statistical Analysis 
All experiments were repeated at least thrice. Values are expressed as means ±  SD and analyzed 
using one way ANOVA followed by LSD test for comparisons of group means, when the F ratios were 
significant. All statistical analyses were performed using SPSS for Windows, version 10 (SPSS, Inc., 
Armonk, NY, USA); a P value < 0.05 is considered statistically significant. 
5. Conclusions  
In  conclusion,  the  present  study  demonstrates  that  pretreatment  with  fucoxanthin  improves  the 
chemotherapeutic  efficacy  of  cisplatin  by  enhancing  the  inhibition  of  cell  proliferation  of  human 
hepatoma HepG2. These effects of fucoxanthin may involve the inhibition of NFκB expression and the 
increase in Bax/Bcl-2 mRNA ratios regulated by NFκB, as well as the decrease of DNA repair systems 
regulated by ERK, p38 and PI3K/AKT, leading to sensitized cancer cells to apoptosis induced by 
cisplatin. The results suggest that the combined treatment of fucoxanthin and cisplatin may provide a 
novel therapeutic approach to decrease cisplatin-induced drug resistance. 
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